Monitoring Adalimumab Autoantibodies in Uveitis Patients
Author Information
Author(s): Lynn S. zur Bonsen, Vitus A. Knecht, Anne Rübsam, Dominika Pohlmann, Uwe Pleyer
Primary Institution: Charité—Universitätsmedizin Berlin
Hypothesis
Routine monitoring may be more effective than selective testing in the long-term management of adalimumab treatment.
Conclusion
Higher AAA concentrations are associated with lower adalimumab serum levels in uveitis patients, highlighting the need for routine clinical testing.
Supporting Evidence
- A significant correlation was observed between AAA levels and reduced adalimumab serum levels (r = −0.58, p < 0.001).
- The mean time to AAA detection was 2.1 years.
- 45.6% of cases were identified through routine testing.
- Higher AAA concentrations were associated with a shorter time to detection (r = −0.27, p = 0.01).
- Younger age was associated with higher AAA concentrations (r = −0.21, p = 0.03).
Takeaway
This study shows that checking for specific antibodies in patients taking adalimumab can help doctors make better treatment decisions.
Methodology
Retrospective analysis of medical records of patients with non-infectious uveitis who developed AAA while undergoing adalimumab therapy.
Potential Biases
Potential biases due to incomplete data on vaccinations and infections.
Limitations
The study's retrospective nature limits control over confounding factors and introduces biases.
Participant Demographics
Average age of 42.5 years, 61.4% female, with various uveitis subtypes.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website